Belite Bio, INC

Hao-Yuan Chuang, Chief Financial Officer and a Director of Belite Bio, Inc, sold 367 shares of common stock on August 12, 2026.

Yu-Hsin Lin, Chief Executive Officer and a Director of Belite Bio, Inc, sold 365 shares of common stock on August 12, 2026.

Hendrik Peter Scholl, Chief Medical Officer of Belite Bio, Inc., reported the sale of American depositary shares totaling 7,820 shares on June 16, 2026.

Chief Scientific Officer Nathan L. Mata sold 666 American depositary shares of Belite Bio, Inc. via a Rule 10b5-1 trading plan.

Belite Bio's Chief Scientific Officer, Nathan L. Mata, reported the sale of American depositary shares under a pre-arranged trading plan.

Belite Bio's Chief Scientific Officer, Nathan L. Mata, reported the sale of American depositary shares under a pre-arranged trading plan.

Yu-Hsin Lin, CEO and Chairman of Belite Bio, Inc., has filed a Schedule 13G, reporting beneficial ownership of 3.1% of the company's ordinary shares as of March 31, 2026.

Darwin Global Management, Ltd., along with its Master Fund and CIO Dr. Abhishek Trehan, has disclosed a beneficial ownership of 7.0% in Belite Bio, Inc.'s ordinary shares.

Yu-Hsin Lin, CEO and Chairman of BELITE BIO, INC., has reported a beneficial ownership of 7.1% of the company's ordinary shares as of December 31, 2024, through a Schedule 13G filing.

Lin Bioscience International Ltd. has reported a beneficial ownership of 53.7% in Belite Bio, Inc., making it a majority shareholder.